gram-negative rod with peritrichous flagella which produces oxidase and catalase, reduces nitrate, oxidizes glucose and xylose, and grows well on cetrimide agar (16) . A. xylosoxidans is an infrequent but potentially serious nosocomial pathogen with a predilection for compromised patients (2, (6) (7) (8) (9) (10) (11) (12) (13) (14) . Community-acquired infections are mainly confined to the middle ear (12, 15) . Resistance to multiple antibiotics is fairly constant among clinical isolates of this organism, perhaps because of the failure of antibiotics to accumulate intracellularly or the presence of P-lactamases (5) . A. xylosoxidans has been isolated from a number of sites in the environment, including deionized water (13) , nonbacteriostatic saline (7) , and clorhexidine solutions (14) . It may exist in the colons and the lower ilea of healthy persons (3) , and can apparently contaminate clinical samples such as blood, urine, and peritoneal fluid of patients with no overt signs of infections (12, 13 ).
An unexpected increase in the number of A. xylosoxidans identified within a short period of time in specimens from hospitalized patients prompted an epidemiologic evaluation of cases A total of 11 A. xylosoxidans isolates were analyzed for plasmids by the method described by Kado and Liu (4) , and whole-cell peptide patterns of 10 of these isolates were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (1) . Seven isolates were also examined by Bristol Laboratories, Syracuse, N.Y., for the presence of aminoglycoside-inactivating enzymes.
RESULTS
Epidemiologic studies. From June 1985 through January 1986, A. xylosoxidans was isolated 18 times from nine Fig. 1 ). Whole-cell peptide analysis of 10 of these isolates was done by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Fig. 2) Twelve A. xylosoxidans isolates were tested against a battery of antibiotics. All were resistant to amikacin, gentamicin, tobramycin, colistin, cefazolin, ceftriaxone, ceftizoxime, ampicillin, cefotaxime, and chloramphenicol. Another nine antibiotics showed activity, but only moxalactam and ticarcillin-clavulanic acid inhibited all 12 isolates. Six of nine isolates were inhibited by trimethoprimsulfamethoxazole, but none of the isolates was killed by this drug (MBC, >2/38 ,ug/ml). Piperacillin, mezlocillin, cefoperazone, and ticarcillin also exhibited wide differences between bactericidal and bacteriostatic levels against one or more isolates. Only two isolates produced ,-lactamase when tested by an acidometric method (PLAC test kit; Analytab Products, Plainview, N.Y.), and they were both from patient 1. Seven isolates, each from a different patient, were tested for aminoglycoside-inactivating enzymes by Bristol Laboratories, but none were found.
DISCUSSION
Judging from the few published reports, nosocomial outbreaks of A. xylosoxidans are distinctly rare, yet a number of common features are apparent. Infected patients usually have serious underlying illnesses, the outbreaks are shortlived, and an environmental source is commonly but not convincingly implicated. Mortality rates of systemically infected patients tend to be elevated, probably because of the patient population affected and because A. xylosoxidans is resistant to most of the antibiotics available. The outbreak in our hospital was similar to those in others in that seven serious or critically ill patients were involved and the responsible organism was resistant to many antibiotics. In addition, if not the primary cause of death, A. xylosoxidans was a significant contributing factor in the deaths of four of the nine patients (44%) that harbored the organism. A fifth patient died after discharge from the hospital. Although an environmental source of infection was not identified, it appeared that the organism was being transmitted from person to person by cross-contamination since the cases were clustered in the MICU and the fifth floor of the hospital. We reasoned that no more than one or two strains of such an infrequently isolated pathogen could have been involved in this limited outbreak. To our surprise, however, plasmid and peptide analyses failed to corroborate this impression since no molecular identity could be established between isolates from different patients. These analyses were methodologically sound since they have been validated previously (1) , and all isolates from the same patients were identical in plasmid content and peptide pattern. In addition, the plasmid and peptide profiles were stable on passage of the isolates. Perhaps the organisms were readily able to exchange genetic material with other clinical or environmental organisms, or the variability may have resulted from the effect of some mobile genetic element. The two communityacquired isolates were just as resistant to antibiotics as were the nosocomial ones, even though they contained no plasmids. A. xylosoxidans was isolated once during the 12 months after the outbreak subsided.
A finding which deserves emphasis was the inability of trimethoprim-sulfamethoxazole to kill any A. xylosoxidans isolates tested during this outbreak, even though growth inhibition was demonstrated, suggesting that this drug should not be used in neutropenic patients infected with this organism. This phenomenon has been described previously in a single isolate ofA. xylosoxidans (11) . Tolerance was also observed with ticarcillin, mezlocillin, piperacillin, and cefoperazone. Only an agent which is shown to be bactericidal in vitro should be relied on for treating life-threatening A. xylosoxidans infections in the patients that are typically infected with this organism. The peculiar results of the molecular studies are difficult to reconcile with the epidemiologic evidence. Further scrutiny of these strains and those involved in future outbreaks might provide an explanation. 
